Home LiteratureArticle Details
PMID: 6193869 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review

Fibrin as a component of the tumor stroma: origins and biological significance.

Cancer metastasis reviews ·Vol. 2 ·No. 1 ·1983-00-00 ·Pages 41-73

Dvorak HF, Senger DR, Dvorak AM

Abstract

An association between cancer and the coagulation system was suggested by Trousseau more than a century ago and initial reports of fibrin deposition in the stroma of solid tumors date back some 25 years. However, the validity and generality of these observations have only quite recently been established, and their implications for an understanding of tumor biology, metastasis, and therapy are only now coming to be appreciated by investigators in the mainstream of cancer research. This article reviews the current status of fibrin's role in the biology of tumor growth, considering in turn: (1) the evidence that fibrin is present in tumors, the nature of such fibrin, and its relation to plasma fibronectin; (2) the mechanisms by which fibrin may come to be deposited in tumors; and (3) the potential biological and medical significance of tumor-associated fibrin deposition and degradation. Among the last are such important possibilities as a barrier function to the immune response and possible roles in angiogenesis, desmoplasia, and metastasis.

MeSH Terms
Animals Blood Coagulation Capillary Permeability Cell Division Cell Line Fibrin/physiology Humans Immunity, Cellular Lymph Nodes/pathology Lymphocytes/pathology Neoplasm Metastasis Neoplasms/immunology,pathology,physiopathology Neoplasms, Experimental/pathology,physiopathology Neovascularization, Pathologic
Chemicals
Fibrin
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Dvorak H F
Senger D R
Dvorak A M
References (139)
139 references, click to expand
  1. Clot forming and clot stabilizing enzymes from the mouse tumor YPC-1.
    Biochem Biophys Res Commun. 1966 Sep 8;24(5):776-81 PMID: 5970512
  2. Pepstatin, an inhibitor of acid kininogenases and ascites retardant in neoplastic disease.
    Fed Proc. 1979 Dec;38(13):2788-91 PMID: 92421
  3. Quantitative study on thromboplastin in various strains of Yoshida ascites hepatoma cells of rat.
    Gan. 1974 Aug;65(4):289-94 PMID: 4372118
  4. Thrombogenic activity of mouse and human tumors: effects on platelets, coagulation, and fibrinolysis, and possible significance for metastases.
    Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1976 Aug 30;86(3):263-77 PMID: 136101
  5. Purification and characterization of tissue factor apoprotein.
    Methods Enzymol. 1976;45:37-48 PMID: 1012004
  6. Physical stability of cell culture procoagulants detectable in first-stage coagulation factor assays.
    Proc Soc Exp Biol Med. 1972 Feb;139(2):713-5 PMID: 5059067
  7. Isolation of vasoactive peptides from human fibrin and fibrinogen degraded by plasmin.
    Thromb Res. 1978 Dec;13(6):983-94 PMID: 155325
  8. Leukokinin-forming system in the ascitic fluid of a murine mastocytoma.
    Biochem Pharmacol. 1973 Jun 1;22(11):1386-9 PMID: 4353805
  9. Warfarin treatment of mice bearing autochthonous tumors: effect on spontaneous metastases.
    Science. 1968 Dec 27;162(3861):1493-4 PMID: 5700070
  10. Techniques for inhibiting tumor metastases.
    Cancer. 1975 Jan;35(1):5-14 PMID: 1089039
  11. Intrafollicular hyalinosis and arterial hyalinosis of the spleen: histochemical and immunofluorescence studies.
    J Pathol. 1969 Jul;98(3):193-9 PMID: 4187536
  12. The role of serine proteases in the blood coagulation cascade.
    Adv Enzymol Relat Areas Mol Biol. 1979;48:277-318 PMID: 367103
  13. Fibronectins--adhesive glycoproteins of cell surface and blood.
    Nature. 1978 Sep 21;275(5677):179-84 PMID: 357987
  14. Induction of fibroblast chemotaxis by fibronectin. Localization of the chemotactic region to a 140,000-molecular weight non-gelatin-binding fragment.
    J Exp Med. 1981 Feb 1;153(2):494-9 PMID: 7241050
  15. Thromboplastic activity of human ovarian tumours.
    Thromb Res. 1975 Apr;6(4):307-13 PMID: 1135789
  16. Suppressive effect of low molecular weight fibrinogen degradation products on human and rat lymphocytes.
    Thromb Res. 1978 Mar;12(3):523-30 PMID: 653639
  17. Fibronectin.
    Prog Hemost Thromb. 1980;5:111-51 PMID: 6999530
  18. Tumors, mucus production, and hypercoagulability.
    Ann N Y Acad Sci. 1974;230:262-70 PMID: 4522873
  19. Thromboplastic and fibrinolytic properties of three transplantable rat tumours.
    Acta Chir Scand. 1970;136(5):365-8 PMID: 4325785
  20. Comparison of procoagulant activities in extracts of normal and malignant human tissue.
    J Natl Cancer Inst. 1979 Apr;62(4):773-6 PMID: 285292
  21. Diffusible thromboplastins of human cancer and chorion tissue.
    Eur J Cancer. 1968 Jan;3(6):467-73 PMID: 5636116
  22. Tissue-factor coagulant activity of cultured human endothelial and smooth muscle cells and fibroblasts.
    Blood. 1977 Sep;50(3):387-96 PMID: 884317
  23. A FACTOR CAPABLE OF INCREASING VASCULAR PERMEABILITY PRESENT IN LYMPH NODE CELLS. A POSSIBLE MEDIATOR OF THE DELAYED REACTION.
    Immunology. 1963 Sep;6:484-98 PMID: 14069726
  24. Detection of antigens of a new diethylnitrosamine-induced transplantable hepatoma by delayed hypersensitivity.
    J Natl Cancer Inst. 1968 Jul;41(1):13-29 PMID: 4298551
  25. Tissue factor activity of normal and neoplastic cells: quantitation and species specificity.
    J Natl Cancer Inst. 1983 Mar;70(3):551-7 PMID: 6601203
  26. New vasoconstrictor, bovine peptide B, released during blood coagulation.
    Nature. 1967 Jul 15;215(5098):292-3 PMID: 4293844
  27. Bulk transfer of fluid in the interstitial compartment of mammary tumors.
    Cancer Res. 1975 Nov;35(11 Pt 1):3084-8 PMID: 1182701
  28. Purification and characterization of bovine tissue factor.
    J Biol Chem. 1981 Aug 25;256(16):8324-31 PMID: 6790539
  29. Radioimmunoassay of fibrinopeptides in relation to intravascular coagulation and thrombosis.
    N Engl J Med. 1976 Aug 19;295(8):428-32 PMID: 59314
  30. Inhibition of lymphocyte protein synthesis by fibrinogen-derived peptides.
    J Immunol. 1982 Apr;128(4):1595-8 PMID: 7061843
  31. Localization of intracranial tumors. Comparative study with 131-I-labeled antibody to human fibrinogen and neohydrin-203Hg.
    Cancer. 1967 May;20(5):751-5 PMID: 6024287
  32. Generation of chemotactic activity for leukocytes by the action of thrombin on human fibrinogen.
    Nat New Biol. 1973 May 9;243(123):56-7 PMID: 17315370
  33. Interaction between 'sensitized lymphocytes' and antigen in vitro. V. Vascular permeability induced by skin-reactive factor.
    Int Arch Allergy Appl Immunol. 1972;42(1):50-68 PMID: 4621854
  34. Tissue factor in cultured cells: metabolic control.
    Lab Invest. 1976 Dec;35(6):542-9 PMID: 1033435
  35. Mononuclear cell tissue factor: cell of origin and requirements for activation.
    Blood. 1979 Aug;54(2):359-70 PMID: 454843
  36. Immune complex-induced human monocyte procoagulant activity. I. a rapid unidirectional lymphocyte-instructed pathway.
    J Exp Med. 1981 Sep 1;154(3):892-906 PMID: 7276829
  37. Mitogenic activity of blood components. I. Thrombin and prothrombin.
    Proc Natl Acad Sci U S A. 1975 Jan;72(1):131-5 PMID: 1054489
  38. A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases.
    Cancer Res. 1973 Jun;33(6):1217-24 PMID: 4718672
  39. The activation of coagulation by extracts of mucus: a possible pathway of intravascular coagulation accompanying adenocarcinomas.
    J Lab Clin Med. 1973 Aug;82(2):255-66 PMID: 4352814
  40. Leukocyte procoagulant activity: enhancement of production in vitro by IgG and antigen-antibody complexes.
    J Clin Invest. 1977 Mar;59(3):549-57 PMID: 190271
  41. Increased production and expression of tissue thromboplastin-like procoagulant activity in vitro by allogeneically stimulated human leukocytes.
    J Clin Invest. 1978 Sep;62(3):649-55 PMID: 151101
  42. Expression of cell-mediated hypersensitivity in vivo--recent advances.
    Int Rev Exp Pathol. 1980;21:119-94 PMID: 6993390
  43. Human breast carcinoma: fibrin deposits and desmoplasia. Inflammatory cell type and distribution. Microvasculature and infarction.
    J Natl Cancer Inst. 1981 Aug;67(2):335-45 PMID: 6267343
  44. Tumor fluid thromboplastin activity.
    Int J Cancer. 1968 Sep 15;3(5):677-82 PMID: 5724526
  45. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation.
    J Lab Clin Med. 1981 Dec;98(6):917-28 PMID: 7310230
  46. Localization in vivo of radio-iodinated anti-rat-fibrin antibodies and radio-iodinated rat fibrinogen in the Murphy rat lymphosarcoma and in other transplantable rat tumors.
    J Natl Cancer Inst. 1959 Feb;22(2):413-26 PMID: 13631502
  47. Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products.
    J Immunol. 1979 Jan;122(1):166-74 PMID: 762415
  48. Immunologic rejection of diethylnitrosamine-induced hepatomas in strain 2 guinea pigs: participation of basophilic leukocytes and macrophage aggregates.
    J Exp Med. 1973 Mar 1;137(3):751-75 PMID: 4347597
  49. Delayed hypersensitivity in man: effects of systemic anticoagulation.
    Science. 1978 May 5;200(4341):541-3 PMID: 644314
  50. Presence of A-type and absence of C-type virus particles in a chemically induced guinea pig hepatoma.
    J Natl Cancer Inst. 1974 Aug;53(2):591-3 PMID: 4135601
  51. Occult cancer in patients with acute pulmonary embolism.
    Ann Intern Med. 1982 May;96(5):556-60 PMID: 7073147
  52. An association between actin and the major histocompatibility antigen H-2.
    Nature. 1978 May 25;273(5660):274-8 PMID: 565878
  53. Macrophage production of fibronectin, a chemoattractant for fibroblasts.
    J Immunol. 1981 Aug;127(2):673-8 PMID: 6166682
  54. STUDIES ON THE PHYSIOLOGICAL ACTIVITY OF THE PEPTIDE RELEASED DURING THE FIBRINOGEN-FIBRIN CONVERSION.
    Biochim Biophys Acta. 1964 Jun 8;86:535-42 PMID: 14192905
  55. The chemotactic activity of fibrin lysis products.
    Int Arch Allergy Appl Immunol. 1972;43(6):879-86 PMID: 4267205
  56. The role of human T cells (and T cell products) for monocyte tissue factor generation.
    J Immunol. 1980 Aug;125(2):606-9 PMID: 6967082
  57. Fibrin and cancer.
    Br Med J. 1971 Dec 11;4(5788):641-2 PMID: 5134558
  58. Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukaemia.
    Br J Haematol. 1973 Jan;24(1):89-99 PMID: 4577065
  59. Thromboplastic and fibrinolytic activities of cultured human cancer cell lines.
    Br J Cancer. 1979 Jan;39(1):15-23 PMID: 758928
  60. Immunosuppression by micromolecular fibrinogen degradation products in cancer.
    Nature. 1976 Feb 5;259(5542):399-401 PMID: 1250379
  61. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.
    Science. 1983 Feb 25;219(4587):983-5 PMID: 6823562
  62. Basophilic leukocytes in allergic contact dermatitis.
    J Exp Med. 1972 Feb 1;135(2):235-54 PMID: 5060290
  63. Evidence that cells from experimental tumours can activate coagulation factor X.
    Br J Cancer. 1979 Aug;40(2):228-33 PMID: 573131
  64. Characterization of the coagulant activity of cultured human fibroblasts.
    Blood. 1971 Jan;37(1):47-51 PMID: 5539131
  65. Leukokinins; their pharmacological properties and role in the pathology of fluid (ascites) accumulation.
    Agents Actions. 1978 Jan;8(1-2):80-4 PMID: 76439
  66. Acute promyelocytic leukemia: a model for understanding the role of the malignant cell in hemostasis.
    Hum Pathol. 1974 Nov;5(6):661-73 PMID: 4607877
  67. Comparative studies on blood coagulation factor XIII.
    Proc Soc Exp Biol Med. 1978 May;158(1):68-72 PMID: 96450
  68. Coagulative properties of cancers.
    Ir J Med Sci. 1958 Oct;394:474-9 PMID: 13586996
  69. Location of the cell-attachment site in fibronectin with monoclonal antibodies and proteolytic fragments of the molecule.
    Cell. 1981 Oct;26(2 Pt 2):259-67 PMID: 6174240
  70. Rationale and experimental design for the VA Cooperative Study of Anticoagulation (Warfarin) in the Treatment of Cancer.
    Cancer. 1979 Aug;44(2):732-41 PMID: 383261
  71. Pepstatin, an inhibitor of leukokinin formation and ascitic fluid accumulation.
    Cancer Res. 1975 Mar;35(3):706-10 PMID: 46779
  72. Renal disease.
    Am J Pathol. 1977 Oct;89(1):183-272 PMID: 143893
  73. Anticoagulants in the treatment of cancer.
    Eur J Cancer. 1976 Oct;12(10):755-62 PMID: 789079
  74. Aggregation of platelets and cell membrane vesiculation by rat cells transformed in vitro by Rous sarcoma virus.
    Cancer Res. 1978 Sep;38(9):2950-5 PMID: 209891
  75. Hematologic changes and thromboembolic complications in neoplastic disease and their relationship to metastasis.
    J Med. 1975;6(5-6):433-58 PMID: 130433
  76. A difference between plasma and cellular fibronectins located with monoclonal antibodies.
    Cell. 1981 Jul;25(1):133-41 PMID: 6168385
  77. Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man.
    J Exp Med. 1973 Sep 1;138(3):686-98 PMID: 4580465
  78. Immune complex-induced human monocyte procoagulant activity. II. Cellular kinetics and metabolic requirements.
    J Immunol. 1982 Mar;128(3):1037-42 PMID: 6173415
  79. Plasmin and plasminogen activators: kinetics, and kinetics of plasminogen activation.
    Ann N Y Acad Sci. 1981;370:588-91 PMID: 6455955
  80. Differences in domain structures between plasma and cellular fibronectins.
    J Biol Chem. 1981 Nov 10;256(21):11292-300 PMID: 7287767
  81. Shedding from the cell surface of normal and cancer cells.
    Adv Cancer Res. 1980;32:75-199 PMID: 7008543
  82. Chemotaxis for human monocytes by fibrinogen-derived peptides.
    Br J Haematol. 1976 Apr;32(4):507-13 PMID: 1259932
  83. Fibrin deposits in Hodgkin's disease.
    Am J Pathol. 1982 Jul;108(1):119-29 PMID: 7046453
  84. The epsilon-(gamma-glutamyl)lysine crosslink and the catalytic role of transglutaminases.
    Adv Protein Chem. 1977;31:1-133 PMID: 73346
  85. Effect of fibrin degradation products on microvascular permeability.
    Thromb Res. 1978 Dec;13(6):995-1006 PMID: 749269
  86. Murine tumor cell activity on in vitro hemostasis.
    Biomedicine. 1976 Sep 30;25(7):252-4 PMID: 990385
  87. Fibrin in human tumors.
    Cancer Res. 1960 Jun;20:592-3 PMID: 14401942
  88. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue.
    Thromb Res. 1975 Feb;6(2):127-37 PMID: 234638
  89. Thromboplastic and fibrinolytic activities of V2 and V7 carcinomas of rabbit, with special reference to fibrin deposition and thrombus formation in the tumors.
    Acta Pathol Jpn. 1978 Mar;28(2):279-86 PMID: 676749
  90. Malignancy and haemostasis.
    Br J Haematol. 1980 Feb;44(2):173-82 PMID: 6990959
  91. Tumor shedding and coagulation.
    Science. 1981 May 22;212(4497):923-4 PMID: 7195067
  92. High molecular weight, cell surface-associated glycoprotein (fibronectin) lost in malignant transformation.
    Biochim Biophys Acta. 1978 Sep 18;516(1):1-25 PMID: 361081
  93. Structure-activity relationships of vasoactive peptides derived from fibrin or fibrinogen degraded by plasmin.
    Biochim Biophys Acta. 1980 Feb 27;621(2):169-78 PMID: 7353036
  94. Rejection of first-set skin allografts in man. the microvasculature is the critical target of the immune response.
    J Exp Med. 1979 Aug 1;150(2):322-37 PMID: 379265
  95. 131-I-labeled antibodies to human fibrinogen. Diagnostic studies and therapeutic trials.
    Cancer. 1967 May;20(5):865-70 PMID: 6024295
  96. Fibrin: structure and interactions.
    Semin Thromb Hemost. 1982 Jan;8(1):11-24 PMID: 7036348
  97. A proteolytic procoagulant associated with malignant transformation.
    J Histochem Cytochem. 1981 Mar;29(3A Suppl):457-63 PMID: 7016982
  98. A factor with procoagulant activity produced by stimulated human leukocyte cultures.
    Clin Immunol Immunopathol. 1980 Nov;17(3):363-71 PMID: 7428188
  99. Molecular mechanism of physiological fibrinolysis.
    Nature. 1978 Apr 6;272(5653):549-50 PMID: 151233
  100. Variations in the staining characteristics of human fibrin.
    Am J Pathol. 1957 Mar-Apr;33(2):267-83 PMID: 13402886
  101. Cellular adhesiveness and extracellular substrata.
    Int Rev Cytol. 1978;53:65-144 PMID: 208994
  102. Proteinaceous precipitate in nodular (follicular) lymphomas.
    Cancer. 1973 Mar;31(3):532-42 PMID: 4348333
  103. Hemostatic abnormalities associated with malignant diseases.
    Eur J Cancer. 1977 Oct;13(10):1053-64 PMID: 336374
  104. A mechanism of migration inhibition in delayed-type hypersensitivity reactions. II. Lymphokines promote procoagulant activity of macrophages in vitro.
    J Immunol. 1981 Mar;126(3):1059-65 PMID: 7462626
  105. Antibody-induced modulation and shedding of mammary tumor virus antigens on the surfaces of GR ascites leukemia cells as compared with normal antigens.
    J Natl Cancer Inst. 1976 May;56(5):1019-29 PMID: 186612
  106. Blood coagulation and the inflammatory response.
    Semin Hematol. 1977 Oct;14(4):391-408 PMID: 144322
  107. Immunohistochemical studies of antibodies in anti-Murphy lymphosarcoma sera.
    Cancer Res. 1959 Sep;19:874-9 PMID: 14401940
  108. A factor X-activating cysteine protease from malignant tissue.
    J Clin Invest. 1981 Jun;67(6):1665-71 PMID: 7016920
  109. Fibrinogen kinetics in patients with neoplastic disease.
    Cancer. 1978 Mar;41(3):1113-22 PMID: 638954
  110. Thrombin active site regions required for fibroblast receptor binding and initiation of cell division.
    J Biol Chem. 1980 Jul 25;255(14):6609-16 PMID: 7391037
  111. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin.
    J Biol Chem. 1980 Nov 10;255(21):10081-90 PMID: 6448846
  112. Association of tissue factor activity with the surface of cultured cells.
    J Clin Invest. 1975 Apr;55(4):814-24 PMID: 47334
  113. Demonstration of fibrin in early stages of experimental metastases.
    Cancer Res. 1976 Jun;36(6):1904-9 PMID: 1268844
  114. Disseminated intravascular coagulation in cancer patients: supportive evidence.
    Cancer. 1973 May;31(5):1114-9 PMID: 4705149
  115. Cancer cell procoagulant activity: evaluation by an amidolytic assay.
    Thromb Res. 1980 May 1-15;18(3-4):589-95 PMID: 6774439
  116. Tumor angiogenesis.
    Adv Cancer Res. 1974;19(0):331-58 PMID: 4605404
  117. Leukokinin-H generated from human ascites fluid; its isolation and pharmacology.
    Agents Actions. 1979 Aug;9(3):265-74 PMID: 91314
  118. Role of the clotting system in cell-mediated hypersensitivity. II. Kinetics of fibrinogen/fibrin accumulation and vascular permeability changes in tuberculin and cutaneous basophil hypersensitivity reactions.
    J Immunol. 1975 Jan;114(1 Pt 2):377-87 PMID: 1090656
  119. Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure.
    J Clin Invest. 1980 Nov;66(5):1033-43 PMID: 6448866
  120. The kinetics and metabolic requirements for direct lymphocyte induction of human procoagulant monokines by bacterial lipopolysaccharide.
    J Immunol. 1981 Jul;127(1):357-63 PMID: 6165771
  121. Thrombophlebitis in cancer patients.
    Ann N Y Acad Sci. 1981;370:138-44 PMID: 6943957
  122. Lodgement and extravasation of tumour cells in blood-borne metastasis: an electron microscope study.
    Br J Cancer. 1978 Aug;38(2):293-301 PMID: 698045
  123. Tissue factor activity in lymphocyte cultures from normal individuals and patients with hemophilia A.
    J Clin Invest. 1973 Jun;52(6):1427-34 PMID: 4634046
  124. Interstitial fluid volume: local regulatory mechanisms.
    Physiol Rev. 1981 Jul;61(3):556-643 PMID: 7019943
  125. Comparison of procoagulant activity in tissue culture medium from normal and transformed fibroblasts.
    Cancer Res. 1978 Aug;38(8):2467-72 PMID: 208769
  126. Species differences of clotting factors in ox, dog, horse, and man: thromboplastin and proconvertin.
    Acta Physiol Scand. 1957 Dec 31;41(4):301-24 PMID: 13497778
  127. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features.
    Medicine (Baltimore). 1977 Jan;56(1):1-37 PMID: 834136
  128. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75.
    JAMA. 1981 Feb 27;245(8):831-5 PMID: 6257941
  129. Follicular lymphoma with deposits of amorphous hyaline material.
    J Pathol. 1974 Jan;112(1):27-31 PMID: 4135072
  130. The extract from the tissue of gastric cancer as procoagulant in disseminated intravascular coagulation syndrome.
    Thromb Res. 1977 Mar;10(3):457-63 PMID: 854879
  131. Synthesis of thromboplastin protein by a murine macrophage-like cell line.
    Thromb Haemost. 1982 Apr 30;47(2):154-6 PMID: 7101235
  132. Properties of leukokininogen isolated from human neoplastic ascites.
    Biochem Pharmacol. 1979 Apr 1;28(7):1043-50 PMID: 87196
  133. Some relationships among hemostasis, fibrinolytic phenomena, immunity, and the inflammatory response.
    Adv Immunol. 1969;10:145-227 PMID: 4242699
  134. Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression.
    J Natl Cancer Inst. 1979 Jun;62(6):1459-72 PMID: 286118
  135. Reed-Sternberg cells in Hodgkin's disease contain fibronectin.
    Blood. 1981 Feb;57(2):339-42 PMID: 7004537
  136. Delayed-type hypersensitivity skin reactions in congenital afibrinogenemia lack fibrin deposition and induration.
    J Clin Invest. 1979 Jun;63(6):1302-6 PMID: 447844
  137. Cell surface shedding--the phenomenon and its possible significance.
    J Theor Biol. 1976 Oct 21;62(2):253-70 PMID: 792575
  138. Data for defining fibrinogen and its plasmic degradation products.
    Thromb Diath Haemorrh. 1975 Apr 30;33(2):199-207 PMID: 49086
  139. Leukocyte procoagulant activity in man: an in vitro correlate of delayed-type hypersensitivity.
    J Immunol. 1982 Jan;128(1):331-6 PMID: 6172485
Article Info
Journal
Cancer metastasis reviews
Abbr.
Cancer Metastasis Rev
ISSN
0167-7659
DOI
10.1007/BF00046905
Published
1983-00-00
Pages
41-73
Language
English
Region
Netherlands
NLM ID
8605731
Subset
IM
Grants
NCI NIH HHS · CA-28471 · United States
NCI NIH HHS · CA-28834 · United States
External Links
PubMed source DOI: 10.1007/BF00046905 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2